RA Capital Management’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
– Sell
-7,856,612
Closed -$365M – 68
2023
Q2
$365M Hold
7,856,612
– – 6.89% 4
2023
Q1
$225M Buy
7,856,612
+1,007,701
+15% +$29.8M 5.1% 3
2022
Q4
$214M Buy
6,848,911
+1,640,000
+31% +$53.5M 4.33% 4
2022
Q3
$106M Hold
5,208,911
– – 2.25% 12
2022
Q2
$80.8M Hold
5,208,911
– – 2.16% 14
2022
Q1
$100M Hold
5,208,911
– – 2.17% 11
2021
Q4
$132M Hold
5,208,911
– – 2.32% 10
2021
Q3
$171M Buy
+5,208,911
New +$177M 2.36% 12

RA Capital Management's DICE Position: Q3 2023 in Review

RA Capital Management sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 7,856,612 shares — an estimated $365M sold.

RA Capital Management first reported a position in DICE in Q3 2021 and held it in 8 quarters. The position peaked at $365M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

  • RA Capital Management reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • RA Capital Management sold 7,856,612 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $365M.
  • RA Capital Management first reported a position in DICE Therapeutics, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
  • RA Capital Management's DICE Therapeutics, Inc. Common Stock position peaked at $365M in Q2 2023.
  • 0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on RA Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.